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INTRODUCTION
Viruses are responsible for up to 10-15% of all 
human cancers1-5. The American Association for 
Cancer Research (AACR) established in 2017 that 
infectious pathogens are the third cause of cancer 
worldwide. Human Papillomavirus (HPV) is con-
sidered to be the second cause of virus-related can-
cer, as it is associated to the 30% of infection-re-
lated cancer cases. It is preceded by Helicobacter 
pylori (32.5%) and closely followed by HBV/HCV 
(29.5%)3. Infectious agents-related cancers are of 
particular interest for a number of reasons. First 
of all, they allow to determine cellular and genet-
ic mechanisms involved in cancer development. 
Secondly, but maybe more importantly, it could be 
possible to use selected screening programs, moni-
toring and vaccination to fight them6-10. 
HPVs are a group of DNA-viruses that cause one 
of the most common sexually transmitted infections 
worldwide11. The infection is generally asymptom-
atic, self-limiting, and the virus is normally cleared 
by the host’s immune system12. HPV serotypes are 
divided in low-risk HPVs (lr-HPVs), and high-risk 
HPVs (hr-HPVs). This second group is involved in 
carcinogenesis13. 
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Abstract – Human Papillomavirus (HPV) is considered to be the second cause of virus-related 
cancer, as it is associated to the 30% of infection-related cancer cases. Many studies showed that 
HPV detection in the urinary tract depends on the sample considered. HPV infection in men is often 
detected in the glans, corona, prepuce, shaft of the penis, and distal urethra.
Oncoproteins E6 and E7 play an essential role in the onset of HPV-related cancers, even if their 
expression is not sufficient to transform the host cell. 
Two possible hypotheses are considered in the association HPV-BCs. The first involves an an-
atomical reason. The second hypothesis considers the natural epithelial tropism of HPV. Current 
evidence in literature fails to show strong associations between HPVs and these cancers.
The aim of this review was to identify key data and factors about the potential role of HPV in 
the genesis of BCs.
KEYWORDS: Papillomavirus, HPV, Bladder cancer, Urinary bladder cancer, Urinary tract cancer
1Department of Biomedical and Dental Sciences and MorphoFunctional Imaging, University of Messina, 
 Messina, Italy 
2Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, 
 Messina, Italy
3Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania,
 Philadelphia, PA, USA
4Department of Pharmacological Sciences, Università del Piemonte Orientale “A. Avogadro”, Novara, Italy
5Department of Human Pathology of the Adult and the Developmental Age “G. Barresi”, 
 Unit of Infectious Diseases, University of Messina, Messina, Italy
G. VISALLI1, A. FACCIOLÀ2, F. D’ALEO2, M. R. PINZONE3, F. CONDORELLI4, I. PICERNO1,
G. NUNNARI2, G. F. PELLICANÒ5, M. CECCARELLI2, E. VENANZI RULLO2
2HPV AND URINARY BLADDER CARCINOMA: A REVIEW OF THE LITERATURE
ROLE OF DNA DAMAGE 
AND CHRONIC INFLAMMATION
IN HPV-CARCINOGENESIS
HPV-induced carcinogenesis is a complex process 
following the infection. However, not every infec-
tion ends as cancer. Integration of viral DNA into 
the host genome, inflammation and high levels of 
inflammatory mediators have been reported in cer-
vical neoplastic lesions as well in other cancers41-45. 
The inflammatory process promotes the integration 
of HPV-DNA and, consequently, the cancer progres-
sion, causing genomic instability and increased sus-
ceptibility to DNA damage46. Oncoproteins E6 and 
E7 play an essential role in the onset of HPV-related 
cancers, even if their expression is not sufficient to 
transform the host cell. As a matter of fact, genomic 
instability is necessary to acquire the malignant phe-
notype. E6 and E7 inactivate and/or degrade respec-
tively p53 and pRb suppressor gene-associated pro-
teins. Molecular studies suggest that the HPV related 
oncoproteins E6 and E7 would play a role also in 
bladder carcinogenesis via the same mechanisms47,48. 
Several studies showed that the increase in reac-
tive oxygen species (ROS) and reactive nitrogen spe-
cies (RNS) happening during inflammation, leading 
to oxidative and nitrative stress, is responsible for the 
rupture of cell double-stranded DNA49-52. This kind 
of damage is necessary for hr-HPV integration53. 
Moreover, ROS are able to induce the formation of 
oxidative DNA mutagenic products, promoting car-
cinogenesis especially during viral infections49,50,54-58. 
Therefore, chronic inflammation (Figure 1) can 
increase DNA mutations through ROS/RNS pro-
duction and can promote proliferation. Other works 
about the association of cancer stem cells with in-
fection and inflammation also support this idea50,59.
However, more studies are needed to determine if 
this model can be applied to bladder neoplasms as well.
HPV PREVALENCE 
IN BLADDER CARCINOMA
BC accounts for about 3.2-4% of all cancers world-
wide, and it is considerably more frequent in males 
than in females. Three histological types of cancers 
represent almost the whole amount of the urinary 
bladder cancers: urothelial carcinoma (UC), squa-
mous cell carcinoma (SCC) and adenocarcinoma 
(AD) (Figure 2). UC is the histological type most 
frequently diagnosed, representing more than 90% 
of all cancers identified on this site60. Much lower 
frequency are SCC and AD61. In the past three de-
cades, there was an increasing incidence of bladder 
carcinoma and this aspect has increased interest for 
identification of possible etiological agents. Several 
Many epidemiological studies showed that 
healthy men, who are usually considered only a res-
ervoir, have a higher prevalence of the HPV infec-
tion than healthy women14-16.
A persistent HPV infection has been historically 
identified as the first cause of cervical cancer. Fur-
thermore, recent studies showed that hr-HPVs have 
a role in the development of cancers of other dis-
tricts17,18. A significant association has been demon-
strated for anal-genital and oropharyngeal cancers, 
while there is a debate whether the virus might play 
a role in the development of urinary bladder cancers 
(BC)19-26. The aim of this review was to identify key 
data and factors about the potential role of HPV in 
the genesis of BCs.
DETECTION OF HPV 
IN URINARY TRACT SAMPLES
Many studies showed that HPV detection in the uri-
nary tract depends on the sample considered. HPV in-
fection in men is often detected in the glans, corona, 
prepuce, shaft of the penis, and distal urethra15,27. How-
ever, some previous studies using urine samples were 
not able to detect HPV infection in the urinary tract.
Many authors reported that urine samples are 
not a good sample for HPV detection (0.8-7%), 
while rubbing the urethral-coronal sulcus, the inner 
prepuce, the distal urethra, the glans, the external 
prepuce and the scrotum led to a 10-44% detection, 
depending on the source22,27-29.
However, more recent studies showed how using 
polymerase chain reaction (PCR)-based methods 
the HPV detection improved even in urine sam-
ples16,30-35. These studies show that HPV can infect 
many sites of the urinary tract, especially urethra, 
prostate and urinary bladder.
A study by Kawaguchi et al30 highlighted that 
liquid-based cytology can lead to a 21% detection 
of HPV-DNA in urine samples in patients affected 
by urethritis, a prevalence seven times higher than 
that found in healthy patients. Moreover, findings 
by Piyathilake et al36 showed a substantial to al-
most perfect agreement in the detection of any HPV 
genotype in urine compared to cervical specimens 
regardless of population characteristics. Therefore, 
testing urine for HPV-DNA could become, in the 
future, even a replacement for the classical and an-
noying procedure which is the Pap-test. In addition, 
there is evidence suggesting that HPV infection 
would start on the distal urethra following a sexual 
contact and, from this site, it would ascend through 
into the bladder urothelial epithelium37-40. Further 
studies about sampling and testing techniques are 
needed to understand the utility of detecting HPV-
DNA in urines.
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Although UC of the bladder often showed focal 
squamous differentiation, is different from SCC, 
which contains solely keratin-forming carcinoma 
cells. BCs composed of mixed urothelial and squa-
mous phenotypes are known as UC with squamous 
risk factors have been considered in the develop-
ment of this cancer type, including smoking, cer-
tain industrial exposure, arsenic in drinking water, 
chronic irritation as well as bacterial and viral in-
fection62,63. 
Fig. 1. Role of chronic inflammation in HPV-carcinogenesis.
Fig. 2. Histological types of bladder cancer.
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(BBC). To this latter aim, the same author in 2003, 
considering 99 cases of BBCs, detected HPV-DNA in 
49% of them, the majority of which (64.6%) belong-
ing to serotype 16. These results suggest an etiologi-
cal role of HPV in this type of neoplasm. Moreover, 
this study showed a positive trend in the correlation 
between tumour grade/stage and hr-HPV infection99. 
In a 2007 study, 166 bladder wash samples were 
obtained from 107 patients. The prevalence of all-
types and hr-HPVs infection in bladder cancers was 
15.2% and 8.1%, respectively. Concerning the grad-
ing, in grade 1, 2 and 3 cancers, the infection rate of 
hr-HPV types was 0%, 3.3%, and 10.6%, respective-
ly (trend test: p=0.221). Finally, in Ta, T1, and T2-T4 
tumours, the hr-HPVs infection rate was 0%, 12.5% 
and 18.2%, respectively101. 
Shigehara et al102 in 2011, evaluated HPV-DNA 
in 117 cases of BCs founding the virus in 18 of them 
(15%). In this study, 15 (83%) of the HPV-positive 
cancers showed a non-invasive growth pattern and 
most of them had been classified as low-grade. 
In 2012 Barghi et al106 carried out a cross-sec-
tional study in 82 male patients with BCs and 
their wives. Bladder tissue specimens of patients 
with UCs were analysed for HPV infection using 
a PCR method for subtypes 16 and 18. The results 
showed that 24 (29.3%) BC samples were positive 
for HPV infection. Of these, it was found HPV-18 in 
9 (37.5%) and HPV-16 in 3 (12.5%). In the wives of 
those men, 4 (4.9%) cases showed cellular dyspla-
sia on their Pap-tests. In those women whose hus-
bands had BCs but no HPV infection, the authors 
found no case of dysplasia.
In a study carried out by Kim et al71 the detection 
rate of HPV-DNA was 2-fold higher in a group of 35 
patients with mixed UC/SCC of the bladder (17.5%) 
than the control group of 12 patients with squamous 
metaplasia of the bladder (8.3%). However, due to 
the small sample size, it is not possible establish a 
real statistically significant increase in risk of HPV 
infection in the study group. These findings agree 
with other investigations in which HPV-DNA was 
detected in both UCs and SCCs of the bladder20. 
Shigehara et al107 in a 2013 study provided an 
important evidence that HPVs play an etiologi-
cal role in UC of the bladder. This work involved 
84 female patients with primary BCs. After DNA 
extraction from paraffin-embedded tissue sam-
ples, HPV-DNA and relative genotype were 
checked. The results showed that HPV-DNA was 
detected in 5 (6.0%) of 84 patients. Concerning the 
genotypes, HPV16 was detected in 3 patients, HPV6 
and HPV52 were detected in one case, respectively. 
HPV-DNA detection was more frequent in younger 
patients and in patients with a past cervical cancer. 
In four hr-HPV-positive cases, hr-HPV-DNA was 
present in cancer tissues. Two cases had a history of 
differentiation (UC/SCC)64. UC and SCC represent 
the histologic subtypes most commonly associated 
with HPV-induced cancer. 
Several studies evaluated the potential causative 
role of HPV infection in BC65-68, but the real impact 
in this field is still highly controversial20,22. Even in 
the most up to date studies, there is no agreement 
about the role of HPV in BC, with an extremely 
wide percentage of positive cases ranging from 0 to 
80%20. Some studies suggested that HPV is the most 
important risk factor for development of carcinoma 
in urogenital system16,47,69. Moreover, other studies 
found an association between HPV and SCC of the 
urinary bladder ranging from 0% to 17%70,71.
Two possible hypotheses are considered in the 
association HPV-BCs. The first involves an anatom-
ical reason. The urethra represents a reservoir for 
the virus and because it directly connects urinary 
bladder with genital area, it can represent a natural 
way for viral migration. The second hypothesis con-
siders the natural epithelial tropism of HPV. In fact, 
these viruses infect epithelial cells with a high tis-
sue tropism and affinity for squamous epithelium72. 
This affinity could well explain the probable asso-
ciation between HPV and BCs. However, because 
most BCs are not SCC but UCs, this association may 
be weak in the majority of BCs patients.
Current evidence in literature fails to show 
strong associations between HPVs and these can-
cers. The reduced size of the studies is probably the 
main reason why this association cannot be demon-
strated, but the rarity of this entity makes virtually 
impossible to conduct larger studies.
In the following sections, we reviewed the stud-
ies offering evidence in favour or against the associ-
ation between HPV infection and the three principal 
histological forms of BCs.
Urothelial carcinoma
The first study that showed a HPV prevalence rate 
of 10% in UC/AD was published in 198873. Since 
then, several studies have detected HPV in at least 
a subset of the analysed cases with results of HPV 
prevalence that varied dramatically.
Of 70 studies considered in this review, 50 
showed a HPV detection in BCs, and a cause-effect 
association was found in 20 studies.
StudieS that Showed an aSSociation hPV-uc
Several investigations assigned to HPV a role in the 
genesis of UCs (Table 1)19-21,23,26,47,71,73-114. Khaled et al95 
in 2001 studied the presence of HPV serotypes 16/18 
in 50 BCs using the technic of “in situ hybridization” 
with a HPV-detection on 46% of cases (23/50). Posi-
tivity was 47.8% for SCCs and 36.4% for UCs. More-
over, the authors state that HPV could be implicat-
ed also in the etiology of bilharzial bladder cancer 
5HPV AND URINARY BLADDER CARCINOMA: A REVIEW OF THE LITERATURE
HPV, human papillomavirus; UC, urothelial carcinoma; AD, adenocarcinoma; SCC, squamous cell carcinoma; SQCC, schisto-
somal squamous cell carcinoma; UK, unknown.
TABLE 1. Study that showed an association HPV-Bladder Cancer (UC, SCC, AD).
Year Author Pathology N HPV detec- Detected HPV
     tion (%)  types (number)
     
1988 Kitamura   UC/AD 10 1 (10%) 16 (1)
1991 Bryant   UC/AD 100 12 (12%) 16/18 (12)
1991 Kerley   UC/SCC/AD 27 1 (3.7%) 11 (1)
1992 Chetsanga   UC 44 1 (2.3%) 16 (1)
1992 Shibutani   UC 20 4 (20%) 6/11 (2), 16/18 (1), 31/33 (1)
1992 Anwar   UC/SCC 48 39 (81%) 18 (18), 33 (14), 16 (13)
1993 Yu ST  UC 53 30 (57%) 16 (28), 18 (2)
1993 Wilczynsky   SCC 22 1 (4.5%) 6 (1)
1993 Furihata   UC 90 28 (31%) —
1994 Mincione   UC 18 1 (5.6%) 31/33/51 (1)
1994 Agliano   UC 46 23 (50%) 16 (11), 18 (7), 16/18 (7)
1994 Maloney  UC/SCC 42 1 (4.4%) 18 (1)
1994 Noel   UC 75 2 (2.7%) 16 (2)
1995 Kamel UC/SCC 47 27 (57%) 31 (19), 18 (16), 33 (13)
     16 (10), 11 (10), 6 (13)
1995 Kim   UC 23 8 (35%) 16 (4), 18 (8)
1995 Smetana UC 110 59 (54%) —
1995 LaRue   UC 71 28 (39%) 16 (27), 6/11 (1)
1995 Lopez-Beltran  UC 76 7 (9.2%) 16 (7)
1995 Gopalkrishna  UC 10 1 (10%) 16 (1)
1996 Tenti   UC 79 26 (33%) 16 (21), 18 (8)
1996 Lopez-Beltran  UC 76 7 (9.2%) 16 (7), 6 (1)
1996 Mvula   UC/SCC 36 1 (2.8%) 16 (1)
1997 Chan   UC 20 6 (30%) 18 (6)
1998 Gazzaniga  UC 35 11 (31%) 16 (6), 18 (5)
1999 De Gaetani UC 43 17 (40%) 6/11 (3), 16/18 (6), 31/33/35 (10)
1999 Simoneau  UC 187 16 (8.5%) 16 (6), 6 (3), 11 (3)
1999 Tekin   UC 42 2 (4.8%) 16 (2)
2001 Khaled   UC/SCC/AD 50 23 (46%) 16/18 (23)
2001 Sur   UC 91 1 (1.5%) —
2003 Fioriti   UC 32 1 (3%) 6 (1)
2003 Khaled   UC/SCC 99 48 (49%) 16 (36), 18 (14), 6 (3), 11 (3)
2005 Barghi   UC 59 21 (36%) 18 (17), 6 (4), 33 (3)
2006 Helal   UC/SCC 114 1 (0.9%) 16 (1)
2007 Moonen  UC 107 15 (15%) 18 (3), 16 (2), 6 (1), 11 (1)
     31 (1), 40 (1), 52 (1), UK  (1)
2008 Badawi   UC/SCC 20 9 (45%) 16 (9), 18 (2)
2011 Shigehara   UC/SCC/AD 117 18 (15%) 16 (6), 18 (4), 33 (3), 31 (1)
     52 (1), 56 (1), 58(1), UK  (1)
2011 Cai   UC 78 27 (35%) 16 (4), 18 (6), 31 (3), 45 (5)
2011 Shigehara  AD 6 1 (16.6%) 
2012 Polesel   UC 114 7 (6.1%) 56 (2), 31 (1), 35 (1), 45 (1)
     58 (1), 70 (1)
2012 Barghi   UC 82 24 (29%) 18 (9), 16 (3), UK (12)
2013 Berrada   UC/SCC 43 22 (52%) 18 (21), 31 (1)
2013 Shigehara  UC 84 5 (6%) 16 (3), 6 (1), 52 (1)
2013 Shaker   15 SQCC  SQCC 33.3% 16/18
    UC 76.6%   
  45 UC  SQCC 44.4%,  6/11
    UC 91.6% 
2013 Chapman  SCC 14 3 (21.4%) 16 (2), 35 (1)
2014 Kim   UC 35 6 (17%) 18 (6)
2016 Golovina   UC 101 38 (37.6) 16
2016 Guma   SCC 1 1 (100%) 6/11
2017 Jørgensen SCC 1 1 (100%) 52, 66, 44, 67
2017 Abdollahzadeh  UC 67 15 (22.4%) -
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a group of 125 BC cases, of which 119 were UCs, 
but the authors found no evidence of HPV detection 
in any case. Yavuzer et al126 in 2011 carried out a 
study involving 70 UC tissues that were screened 
by nested-PCR for HPV-DNA with a control group 
of 18 cervical tissues with invasive cervical carcino-
ma and Cervical Intraepithelial Neoplasia III (CIN 
III). In the study group, the authors did not find 
HPV-DNA positivity in any of the considered UCs. 
In 2012, a study of Polesel et al105 considering 114 
UC cases, screened urine samples to detect DNA of 
22 mucosal HPVs using highly sensitive PCR assays. 
HPVs were detected only in seven cases and five con-
trols (OR=1.52; 95% CI: 0.42-5.45). The study does 
not suggest an involvement of HPVs infection in UC 
aetiology in immunocompetent individuals.
Steinestel et al129 in 2013 collected 60 speci-
mens of urothelial carcinoma in situ (UCIS) from 
45 patients, and a control group with CIN. In the 
specimens, the authors performed p16(INK4a) im-
munohistochemistry followed by detection and sub-
classification of HPV-DNA. The results showed the 
presence of hr-HPV-DNA in 80% of CIN, but none 
in UCIS. 
Finally, Schmid et al131 in 2015 conducted a study 
involving 109 cases of BC with 41 superficial (pTa 
low grade) cancers, 56 invasive (pT1-T4) high grade 
cancers and 12 other types (pTa high grade + pTis). 
The authors did not detect HPV-DNA in any sample 
(95% Confidence Interval (CI) 0-3.3%). The results 
suggest that it is improbable that HPV infections can 
play an important role in the development of UC.
cervical cancer with the same HPV type (HPV16) 
detected both from BC and cervical cancer108. 
Golovina et al111 in 2016 collected UC tissue sam-
ples from 101 patients. Morphological analysis and HPV 
biomolecular detection were conducted in the cancer 
specimens. HPV16-DNA was detected in 38 speci-
mens, while mRNA of E6 and E7 oncogenes and E7 
oncoprotein of HPV16 were found in 13 specimens. In 
HPV-positive samples, it was found an association be-
tween HPV detection and a higher degree of cell ana-
plasia than HPV-negative cancers. Moreover, HPV was 
detected in primary BCs more often than in recurrent 
those. These data showed a sure involvement of HPV16 
in the genesis of BC. No correlations were found be-
tween HPV status of BCs and patient’s sex, age, and 
invasion into the muscle layer, which were revealed.
In a 2017 study carried out by Abdollahzadeh et 
al114 in 97 biopsy specimens, including 67 patients 
with UCs and 30 controls, the authors identified 
HPV-DNA in 22.4% of patients with cancers and 
3.3% of controls were positive for HPV. The HPV 
prevalence was 4.3-fold higher in men than women. 
Most UC patients belonged to grades II and III.
Study that refuSeS the aSSociation hPV-uc
In contrast with the above-described studies, a num-
ber of investigations did detect no presence of HPV 
in the evaluated cases (Table 267,70,105,115-131). Many of 
these investigations have included a large patient 
subset as well. For example, Youshya et al67 consid-
ered 78 cases of UCs but any HPV detection was 
observed. Likewise, Ben Selma et al125 investigated 
HPV, human papillomavirus; UC, urothelial carcinoma; AD, adenocarcinoma; SCC, squamous cell carcinoma; UK, unknown.
TABLE 2. Study that refuse the association HPV-Bladder Cancer (UC, SCC, AD).
Year Author Pathology N HPV detec- Detected HPV
     tion (%)  types (number)
     
1992 Knowles  UC/SCC/AD 108 0 (0%) None
1993 Sinclair   UC 14 0 (0%) None
1993 Saltzstein  UC 33 0 (0%) None
1994 Chang   UC 108 0 (0%) None
1995 Sano   BT 93 0 (0%) None
1996 Boucher  UC/SCC 55 0 (0%) None
1997 Lu  UC/SCC/AD 31 0 (0%) None
1997 Cooper   SCC 25 0 (0%) None
1998 Aynaud   UC 57 0 (0%) None
2001 Westenend  SCC 16 0 (0%) None
2005 Youshya   UC 78 0 (0%) None
2009 Guo   SCC 16 0 (0%) None
2010 Ben Selma  UC/SCC/AD 125 0 (0%) None
2011 Yavuzer  UC 70 0 (0%) None
2012 Polesel   UC 114 0 (0%) None
2012 Blochin  SCC 2 0 (0%) None
2012 Alexander  SCC 42 0 (0%) None
2013 Steinestel  CIS 45 0 (0%) None
2014 Alexander  AD 36 0 (0%) None
2015 Schmid   BC 109 0 (0%) None
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A larger and more recent study conducted by Al-
exander et al128 did not find evidence of HPV pres-
ence in 42 SCC cases. Moreover, the same authors 
performed the analysis on 27 cases of UCs with 
squamous differentiation, a morphologically similar 
entity to SCC of the urinary bladder. Even in this 
case, the results showed no evidence of HPV. These 
studies agree with the findings reported on UC with 
squamous differentiation from Blochin et al127 in 
2012. Other previous studies also failed to find HPV 
infection in bladder SCC cases. In conclusion, the 
role of detecting HPVs in the urinary bladder SCC 
is uncertain. HPV infection could have a little or no 
influence in the development of SCC of the bladder, 
but there is necessity of further researches to clarify 
this association. 
adenocarcinoma 
of Urinary bladder (ad)
Even in case of AD of urinary bladder, the litera-
ture is quite poor and conflicting (Table 1 and 2). A 
study carried out by Alexander et al130 on 36 cases 
of clinically confirmed cases of primary AD of the 
urinary bladder has not detected HPV in any of the 
examined cases. Conversely, a large study on BCs 
conducted by Shigehara et al104 evaluated six AD of 
urinary bladder cases founding HPV-DNA in one 
case using PCR method; however, the extremely 
small number of considered specimens, do not allow 
any significant conclusions.
CONCLUSIONS
In the past three decades, the incidence of bladder 
carcinoma increased worldwide inducing the au-
thors to identify possible etiological agents. Among 
the well-known cancer causes (smoking, industrial 
exposure, heavy metals in drinking water, chronic 
irritation) an increasing interest there was about a 
possible role played by HPVs in the pathogenesis of 
this kind of cancers. A thirty years’ literature was 
not able to clearly demonstrate the real contribute 
of HPV in this oncologic disease. The difference 
among the studies is probably due to sampling prob-
lems, contamination, sensitivity of the detection 
systems, geographic variation and size of the stud-
ies, especially regarding the rarer forms129. Further 
studies are required to understand and clarify the 
role of HPV in the pathogenesis of this kind of uri-
nary cancers. 
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SquamouS cell carcinoma (Scc)
The literature concerning the hypothetical role of 
HPV in SCC pathogenesis is poor and provides con-
flicting results. Some investigations have identified 
a link between HPV and this kind of cancer, while 
other studies have reported no association between 
HPVs and SCC pathogenesis (Table 1 and 2).
stUdy that showed an association hPV-scc
Chapman-Fredricks et al110 enrolled 14 cases of 
primary bladder SCC, positive for p16 by immuno-
histochemistry, to detect hr-HPV by in situ hybrid-
ization and the signal amplification Invader assay. 
The results showed that the hr-HPV detection by the 
in-situ hybridization method was negative in all cas-
es. However, in 3 of 14 cases (21.4%), the presence 
of hr-HPV-DNA was detected with the Cervista 
hr-HPV Invader assay, with the subsequent identi-
fication of genotype. hr-HPV type specific amplifi-
cation followed by DNA sequencing confirmed all 
positive cases. Identified genotypes were HPV 16 in 
2 cases and HPV 35 in 1 case. This study concluded 
that hr-HPV-DNA is detectable in a subset of prima-
ry bladder SCCs.
At the same time in 2013 Shaker et al109 investigat-
ed the HPV role on 60 bladder specimens, of which 
15 were schistosomal squamous cell carcinoma 
(SQCC) and 45 were schistosomal and non-schisto-
somal UCs. The results showed that HPV 16/18 were 
found in 33.3%, 50% and 26.6%, respectively, while 
the positivity to HPV 6/11 were 44.4%, 58.3% and 
33.3% for SQCCs, UCs and UC/SCC, respectively. 
Seven cases of UCs had both HPV6/11 and 16/18.
A study carried out in 2016 by Guma et al112 
demonstrates that the infection with HPV 6/11 was 
associated with an UC with squamous differentia-
tion and condylomatous features. This is a case re-
port on a high-grade UC with focal areas of squa-
mous differentiation. These areas showed koilocytic 
differentiation, which was positive for strong p16 
expression. In this cancer, it was found positivity for 
lr-HPV 6/11 by in situ hybridization technic. 
Jorgensen et al113 reported in a case of bladder 
SCC the presence of four different HPV types: 
hr-HPV-52, hr-HPV-66p, lr-HPV-44 and HPV-67. 
However, the association between the risk to devel-
op SCC in the urinary bladder and the multiple in-
fection with different HPV genotypes as seen in this 
patient is still unknown.
Study that refuSeS the aSSociation hPV-Scc
Westenend et al70 in 2001 and Guo et al124 in 2009 
carried out two small investigations involving both 
16 cases of SCC of the urinary bladder. In both stud-
ies no cases of HPV were detected. 
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